Canada NewsWire TORONTO, Oct. 16, 2024 Coordinated programs improve equitable access to screening so cancer can be caught and treated earlier, and more lives can be saved TORONTO, Oct. 16, 2024 /CNW/ - Canada is making excellent progress ...
PR Newswire HONG KONG, Oct. 16, 2024 HONG KONG, Oct. 16, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) (" Akeso", the "Company" ) announced positive results in progression-free survival (PFS) and overall survival (OS) from its Phase 3 ...
PR Newswire NORTH CHICAGO, Ill., Oct. 15, 2024 $1.2 Million Distributed by Mary Kay Ash Foundation Will Fund Promising Cancer Researchers at Top Universities Advancing Cures For Women-Related Cancers NORTH CHICAGO, Ill., Oct. 15, ...
PR Newswire PHILADELPHIA, Oct. 15, 2024 PHILADELPHIA, Oct. 15, 2024 /PRNewswire/ -- Breastcancer.org has released the results of its 2024 insights survey, uncovering important data on the side effects and challenges breast cancer patients ...
PR Newswire DUARTE, Calif. and SAN FRANCISCO, Oct. 15, 2024 Collaboration expands WebTPA's cancer care solution to give employers and their employees access to expertise from top cancer specialists across the U.S. DUARTE, Calif. and SAN ...
PR Newswire NEWPORT BEACH, Calif., Oct. 15, 2024 Invasive lobular carcinoma (ILC), also known as lobular breast cancer,comprises 15% of all breast cancer diagnoses NEWPORT BEACH, Calif., Oct. 15, 2024 /PRNewswire/ -- As part of October ...
PR Newswire AUSTIN, Texas, Oct. 15, 2024 Demonstrated Favorable Safety Profile of REQORSA AUSTIN, Texas, Oct. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company ...
PR Newswire SAN JOSE, Calif., Oct. 15, 2024 Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif., Oct. 15, 2024 ...
PR Newswire FAIRFAX, Va., Oct. 15, 2024 Virginia Cancer Specialists, ranked the #1 practice in Virginia for cancer care and the #2 practice in Virginia across all medical specialties, is committed to providing comprehensive and full-spectrum ...
PR Newswire TEL AVIV, Israel, Oct. 15, 2024 Topline Results Expected in Q1 2025 TEL AVIV, Israel, Oct. 15, 2024 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies ...
New research has developed an immunotherapy for cancer by combining DNase I with CAR T-cell therapy. The research conducted by Xenetic Biosciences titled, "The synergistic action of DNase I and CAR T cells enhances the therapeutic efficacy ...
Anti-EGFR antibody treatment is given to treat patients with metastatic colorectal cancer (CRC). However, due to mutations in the tumor cells, it becomes resistant to the treatment making it less effective ( ). CRC is one of the ...
The term Minimal residual disease (MRD) was first introduced to describe the strong association between MRD detection after treatment and the risk of relapse. MRD is the least amount of cancer cells that remain in the body during or after treatment. The technologies for detecting MRD have evolved along with its potential applications as these technologies are now used for studying MRD in multiple solid tumors. More assays are available even before their clinical use is proven. The assays or tests vary in sensitivity, detection limits and evidence that support their use. Can all Liquid Biopsy Tests Detect MRD? MRD, cell - free DNA(cfDNA) and circulating tumor DNA (ctDNA) are interchangeable under the field of liquid biopsy even though their meanings do not overlap. Their applications are different so it is important to know how they differ. Most current tests detect ctDNA that detects the fraction of cfDNA released by tumor cells. In healthy persons the blood is rich in cfDNA released by dying cells and the ctDNA needs to be deducted from cfDNA. Not all ctDNA tests are MRD detectable tests. MRD tests are highly sensitive and will be able to detect even small traces of ctDNA. But most of the commercially available liquid biopsy tests focus on detecting druggable alteration and tumor features. MRD tests are classified into 2 categories Tumor-informed test : uses archival tumor tissue (tissue embedded in paraffin and stored) to detect tumor specific alteration which is then used to detect MRD in blood. Newer tumor-informed tests can detect thousands of mutations, lowering the limit of detection down to 1 part per million. Tumor-naíve test : blood only tests that use tumor-intrinsic features such as epigenomic profiling and fragment length to identify minimal traces of ctDNA with cfDNA. Tumor-informed tests have the highest sensitivity but their higher cost and longer turnaround times are disadvantages. Can MRD be Used as a Biomarker? Almost all patients who test MRD positive after treatment experience recurrence. MRD can be a powerful prognostic biomarker that can find people with varying cancer risk recurrence. Guiding adjuvant treatment : MRD detection after surgery can be used to personalize adjuvant or post surgery treatment. MRD-positive patients can be treated with targeting residual disease, while MRD-negative patients can avoid the potential toxicity. Adaptive treatment strategies during therapy : MRD clearance during neoadjuvant therapy is viewed as a supplement for treatment response. Researchers are exploring whether MRD status can help mid-treatment adjustments to improve therapy outcome. Recurrence prevention : MRD monitoring during follow up offers advantage over traditional tumor markers by detecting recurrence rate. But it is not clear if early intervention based on this can alter the natural course of disease or if it is an advanced diagnostic sensitivity without changing outcomes. Ultimately, as MRD assays become more advanced and data from ongoing trials become available, MRD has the potential to redefine treatment paradigms, offering more personalized and effective approaches across cancer types. Reference: NCCN Issues Updated Guidance on Genetic Testing for Several Cancers - (https:...
A new study reveals a key mechanism driving skin cancer. Researchers have identified a protein-ion channel interaction that fuels tumor growth. ( ) What is Melanoma Melanoma arising from pigment-producing cells known as melanocytes is the deadliest form of skin ...
While the Centers for Disease Control and Prevention (CDC) advises that reducing alcohol consumption or abstaining can lower cancer risk, data from the Annenberg Public Policy Center (APPC) reveal that fewer than half of Americans are aware that regular alcohol consumption increases the risk of developing cancer later in life. ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers